Semax (N-Acetyl Semax)
The Ground Truth Score
four plain questions, never one numberDecades of Russian use, thin modern human data
Bottom line
A real registered drug in Russia with 30+ years of clinical use and a handful of small human studies, but the published human evidence is mostly small, single-country, and dated, far short of the Western RCT bar, and the N-acetyl variant most people buy is barely studied at all.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
Can you legally get it?
Advisory: yesRecommended, not legal yetAn FDA advisory committee recommended this for the 503A Bulks List in July 2026. Read that precisely: it is a recommendation, not a rule. Nothing changed about what is legal, FDA still has to run notice-and-comment rulemaking, and it can decline. Today this is still bought the same gray-market way it was in June.
Recommended for the 503A Bulks List by the FDA's Pharmacy Compounding Advisory Committee, 8-5, at the July 23-24 2026 meeting. FDA's own briefing documents recommended against adding it. The vote is advisory and binds nothing.
Legal status as of 2026-07-24. This is a separate axis from the grades above, and it does not move them. A vote about who may legally prepare a compound is not evidence that the compound works.
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) intranasal dosing clusters around 100-600 mcg/day, often split into 1-3 doses, with some users going up to ~900 mcg/day; cycles of roughly 10-14 days on / 7+ days off are common in forum protocols.
Reported, not prescribed. Verify your vial and your math.
First documented human use
Human use dates to the early 1990s in Russia; Semax was approved by the Russian Ministry of Health in 1994 for cerebrovascular indications and added to Russia's Essential Drugs List. The earliest English-indexed human clinical reports appear around 1997 (acute ischemic stroke). No large multicenter randomized controlled trial meeting Western regulatory standards has been published, and no FDA-registered trial has been completed.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. We grade each one below.
- Synthetic analog of the ACTH(4-10) fragment with an added Pro-Gly-Pro tail for stability; the N-acetyl version adds an acetyl group claimed to further slow degradation.
- Reported to upregulate BDNF and NGF and to modulate dopamine and serotonin systems, the assumed basis for focus and neuroprotection claims.
- Registered and used clinically in Russia for ischemic stroke, cognitive decline, and optic-nerve disorders for over three decades.
- Delivered intranasally at microgram doses, marketed for focus, mental clarity, and stress resilience.
- Most-cited as half of the 'Russian stack' (Semax for daytime focus, Selank for calm).
The data behind each bullet
What actually backs it
Semax is a registered pharmaceutical in Russia (approved 1994) for cerebrovascular and cognitive indications and appears on Russia's Essential Drugs List.
Russian regulatory approval and decades of clinical use, but that approval is not based on the multicenter RCT package Western regulators require, and confers no FDA equivalence.
PubMed: Semax ischemic stroke (human clinical reports) ↗Small human clinical studies (e.g., acute ischemic stroke cohorts from 1997 onward, and a 2018 functional-MRI study of the brain's Default Mode Network) report neurological/cognitive effects.
These are real human studies but small, largely Russian, and mostly open-label or mechanistic; the 2018 fMRI study provides a rare objective (imaging) human signal but is not an efficacy RCT.
PubMed: Semax (all studies) ↗Semax upregulates BDNF/NGF and modulates dopaminergic and serotonergic systems.
This mechanism is established mainly in rodent and in-vitro work; it is the assumed basis for human cognitive claims, not proof of human cognitive benefit.
PubMed: Semax BDNF neurotrophin ↗No FDA-approved Semax product exists in the US; it is available only via patient-specific 503A compounding and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review.
Regulatory-status fact. Semax was nominated then withdrawn from FDA bulk-compounding Category 2 and is queued for PCAC review (reported July 2026); it is not a controlled substance but cannot be sold as a supplement.
ClinicalTrials.gov: Semax (registered trials search) ↗The N-acetyl modification meaningfully improves stability/potency over plain Semax in humans.
Largely a vendor/theoretical claim. Acetylation plausibly blocks an N-terminal peptidase cleavage site, but there is little to no head-to-head human data distinguishing N-Acetyl Semax from Semax.
PubMed: N-Acetyl Semax ↗Prove it
Can you tell if it's working?
The honest test: if it's working, is there any objective way to see it — a blood marker, a scan, a wearable? For a lot of peptides the answer is no, and that's worth knowing before you spend on labs or gear.
The only objective-ish readout is a structured, ideally blinded on/off cognitive test battery — no wearable, scan, urine, or lab tracks semax efficacy.
Bloodwork
Nothing on a routine panel confirms this one. Anyone who says otherwise is guessing.
Semax is an intranasal ACTH(4-10) analog whose action is confined to the CNS (melanocortin-receptor engagement plus BDNF/NGF and TrkB upregulation in hippocampus and cortex, with dopamine/serotonin modulation); it deliberately lacks ACTH's steroidogenic activity, so it moves no cortisol, ACTH, or other peripheral analyte that a routine panel measures.
Read this before you spend on labs
Routine bloodwork cannot confirm Semax is working. Its effects are cognitive and neuroprotective (focus, memory, stress resilience, stroke recovery) and are mediated centrally by BDNF/NGF and TrkB signaling. The proposed mediator, BDNF, is a research-only ELISA rather than a LabCorp/Quest orderable, and serum BDNF is a noisy, platelet-confounded proxy that poorly reflects brain BDNF, so even off-label it would not prove efficacy. Unlike its parent hormone, the ACTH(4-10) fragment does not stimulate the adrenal axis, so cortisol and ACTH will not track it either. Verify response with validated cognitive or symptom measures (a repeated attention/working-memory task or a target-symptom log), not blood. The only blood-relevant note is a theoretical rise in fasting glucose in diabetics, which is a safety signal, not evidence of benefit.
Other ways to track it
Standardized cognitive test battery run n-of-1 — e.g., psychomotor vigilance task (PVT) reaction time, an n-back working-memory task, or a validated attention/processing-speed app (Cambridge Brain Sciences, CANTAB-style tools)
A working result shows faster and steadier reaction times and better sustained-attention/accuracy scores on-drug versus off, beyond what practice alone explains — best isolated in a randomized, blinded on/off (ideally placebo-controlled) design. A subtle or absent effect is a genuine, expected outcome: the human effect is described as subtle and variable, and a meaningful minority report nothing.
Semax's target effect is CNS attention/processing-speed and mental-fatigue reduction; cognitive performance is the only human-accessible objective readout of that effect. It is confounded by expectancy, practice, caffeine, modafinil/Selank co-use, and sleep, so it is a partial proxy rather than a clean biomarker.
Bottom line
No physiological modality reflects semax in humans — not blood, urine, stool, sleep/HRV, CGM, VO2max, DEXA, or genetics. Its effect is subjective cognition, and the honest tracking tool is a validated cognitive test battery, not a scan or panel. Even that is only a partial proxy: it is heavily confounded by practice effects and expectancy (placebo risk is rated moderate and benefits are expectancy-sensitive), so it is only trustworthy inside a blinded, randomized on/off n-of-1 design. Human evidence overall is weak, dated, and largely Russian open-label; the sole rigorous objective human signal (a 2018 resting-state fMRI Default Mode Network study, Lebedeva et al., n=14 semax vs 10 placebo, acute intranasal) is a small research tool, not a home tracker.
Logging baseline vs retest is the whole game. The Truth Tracker is our free log for bloodwork, DEXA, genetics, and wearable data — bring your own numbers.
How to track it →Mechanism
How it's assumed to work
Assumed · theoretical pathway
Assumed mechanism: Semax is a synthetic analog of the ACTH(4-10) melanocortin fragment (sequence Met-Glu-His-Phe-Pro-Gly-Pro), with the Pro-Gly-Pro tail added to resist enzymatic breakdown; the N-acetyl version adds an N-terminal acetyl group thought to block the first peptidase cleavage site. It is believed to act largely independent of steroidogenic ACTH activity, instead upregulating BDNF and NGF (via CREB signaling) and modulating dopaminergic and serotonergic tone, the presumed basis for neuroprotective and pro-focus effects. This is an assumed/theoretical mechanism derived mostly from animal and in-vitro data, not an FDA-approved indication.
Dosing & handling
What users and clinicians report
Reported (not prescribed) intranasal dosing clusters around 100-600 mcg/day, often split into 1-3 doses, with some users going up to ~900 mcg/day; cycles of roughly 10-14 days on / 7+ days off are common in forum protocols. A 10 mg vial reconstituted to ~2.5 mg/mL yields ~250 mcg per ~0.1 mL spray actuation. These figures come from vendor/community sources, not controlled human dose-finding.
All doses are anecdotal/vendor-derived, not from validated human dose-finding trials, and the N-acetyl variant has no established human dosing of its own. Intranasal microgram dosing makes accurate measurement hard, and gray-market product strength varies, treat any specific number as unverified.
Timing & food
Typically dosed intranasally in the morning and/or midday (and sometimes pre-work/pre-study) to align with its claimed focus/alertness effect and to avoid late-day sleep disruption. Food timing is largely irrelevant because the intranasal route bypasses the gut; users simply clear the nasal passage before spraying. Timing rationale is anecdotal, no controlled chronotiming data exists.
Half-life
Plasma half-life is very short, roughly 2-5 minutes for unmodified Semax, due to rapid degradation by peptidases (enkephalinase/carboxypeptidase). Proponents cite a 'paradox' of minutes-long plasma half-life but hours-to-24h CNS effects via intranasal nose-to-brain delivery; the prolonged-CNS-effect figures are largely extrapolated from labeled-tracer and rodent work and should be read as theoretical, not established human pharmacokinetics. Acetylation is claimed to extend half-life roughly 2-3x.
Reconstitution sensitivity
Supplied as a lyophilized powder; reconstituted with sterile bacteriostatic water or saline for intranasal use. Reported handling: refrigerate (2-8 C) after reconstitution, store upright, protect from light and heat, and use within about 2-4 weeks. Heat/room-temperature storage is said to degrade potency and risk microbial growth. Handling guidance is vendor/community-sourced, not from a regulated label.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate-to-high community volume: Semax is one of the more widely discussed nootropic peptides, with substantial Reddit/Substack/forum and vendor-blog coverage, heavily anchored to the Semax+Selank 'Russian stack.'
Consistency
Fairly consistent themes, clearer thinking, calm/sustained focus without stimulant jitter or crash, and modest mood lift, but effects are described as subtle and variable, and a meaningful minority report little or nothing. Consistency is undercut by near-ubiquitous stacking.
Source credibility
Credibility is mixed and should be discounted: much of the online content is vendor- or affiliate-driven and recycles the same Russian-approval framing, and the genuine user reports are subjective and expectancy-prone. The most credible objective anchor is the small 2018 human fMRI study, not the marketing copy.
- Many users describe 'lifted brain fog' and calm, sustained focus without the jitters or crash of caffeine/stimulants, though they consistently call the effect subtle rather than dramatic (anecdote, not proof).
- It is most often discussed as half of the Semax+Selank 'Russian stack,' with Semax framed as the daytime focus/drive piece and Selank as the calming counterweight, which heavily confounds attribution.
- A notable subset of users report minimal or no perceptible effect, and a few mention mild irritability, headache, or sleep changes, especially at higher or late-day doses.
- Reported tolerability is generally good with no described crash or dependence, but these are unverified self-reports from forums and vendor-adjacent communities and should be discounted accordingly.
Placebo risk, Moderate
Moderate placebo risk. The headline benefits (focus, clarity, calm, motivation) are subjective and expectancy-sensitive, and the ritual of an intranasal spray plus stacking amplifies suggestion. It is not High because there is at least some objective human signal (2018 fMRI Default Mode Network changes) and mechanistic plausibility (BDNF/dopaminergic modulation), but everyday cognitive claims remain largely unblinded and self-reported.
Risk panel
What could go wrong
Adverse events
Reported adverse effects are generally mild: nasal/mucosal irritation from intranasal use, transient headache, occasional fatigue, irritability, sleep or appetite changes, and minor short-lived heart-rate/blood-pressure fluctuations on initiation. Russian sources describe it as well tolerated, but these reports come from small studies without independent Western pharmacovigilance.
Theoretical concerns
As an ACTH/melanocortin fragment, theoretical concerns center on HPA-axis, glucose, and autonomic effects with chronic or supraphysiologic dosing, one source notes increased blood glucose in people with diabetes. Potent BDNF/dopamine modulation in a still-developing or psychiatric brain is incompletely characterized. The N-acetyl variant's pharmacology in humans is essentially uncharacterized.
Contraindications
No formal contraindication list exists from a Western regulator. Reasonable caution applies to pregnancy/breastfeeding (no data), diabetes (possible glucose effect), uncontrolled hypertension/arrhythmia (autonomic effects on initiation), and concurrent serotonergic/dopaminergic psychiatric medication. Gray-market product purity, sterility, and dose accuracy are themselves a risk.
Honest unknowns
The biggest unknowns are long-term safety (no multi-year human data), reproductive/developmental safety, and whether N-Acetyl Semax behaves like plain Semax in humans. Source/purity variability across vendors means the actual molecule and dose in any given vial are uncertain. There is no Western RCT efficacy or safety package.
Confound watch
Most commonly run alongside Selank (the 'Russian stack'), and frequently with caffeine, modafinil, racetams, MK-677, or Cerebrolysin. Daytime focus claims are heavily confounded by these stimulants/nootropics, by sleep and workload changes, and by strong expectancy, making it very hard to attribute any subjective effect to Semax alone.
History
Discovery → first use → status
Update: an FDA advisory panel voted in favor of this one on July 23-24, 2026
The FDA's Pharmacy Compounding Advisory Committee voted 8-5 to recommend adding this to the 503A Bulks List, meaning compounding pharmacies could legally prepare it. Now read the fine print, because it matters more than the headline. The vote is advisory and changes nothing today: FDA still has to go through formal rulemaking, which can take a year, and it has overruled its own panels before. FDA's own scientists recommended AGAINST adding it, citing thin human evidence and unassessed immunogenicity risk, and the committee voted the other way. That committee is also not neutral: most of its recent appointees work at or run clinics that sell peptide treatments. And none of this is a finding that the compound works. A compounding-eligibility vote is not drug approval, and it is not evidence. Our grade here is unchanged, because the evidence did not change.
Vote recorded July 23-24, 2026; verified against FDA's meeting materials and contemporaneous reporting. Nothing here is final — check the current rule before acting.
FDA — PCAC meeting, July 23-24 2026 ↗- 1980sDeveloped at the Institute of Molecular Genetics, Russian Academy of Sciences, as an ACTH(4-10) analog stabilized with a Pro-Gly-Pro tail.
- 1994Approved by the Russian Ministry of Health for cerebrovascular indications; later added to Russia's Essential Drugs List.
- 1997Earliest English-indexed human clinical reports in acute ischemic stroke appear in the literature.
- 2005-2010Rodent studies establish dopaminergic/serotonergic activation and BDNF/NGF transcriptional upregulation as the assumed mechanism.
- 2018Human fMRI study reports Semax effects on the brain's Default Mode Network, a rare objective human data point.
- 2026In the US, reported withdrawn from FDA bulk-compounding Category 2 and scheduled for PCAC review (reported July 24, 2026); remains non-FDA-approved and compounding-only.
Verification
The COA standard, applied
Verified against PubMed (Semax returns ~229 results, overwhelmingly rodent/in-vitro, with only a small minority of human studies, chiefly small Russian stroke cohorts from 1997-2018 and a 2018 fMRI study). Cross-checked regulatory status (non-FDA-approved, 503A compounding, PCAC review) and half-life across multiple sources. NOTE: an automated search summary asserted a '120-patient placebo-controlled RCT' with specific NIHSS/mRS statistics; that specific trial and its numbers could NOT be confirmed in the PubMed listing and were treated as unverified and excluded.
The full verification standard →Sources
Where this comes from
- PubMed. Semax (all indexed studies) ↗· ~229 results, overwhelmingly rodent/in-vitro; human studies are a small minority. Use to gauge the true human-evidence depth.
- PubMed. Semax ischemic stroke (human clinical reports) ↗· Includes the small Russian human stroke studies (1997, 1999, 2018), the core human clinical evidence.
- PubMed. Semax BDNF / neurotrophin (mechanism) ↗· Mostly rodent/in-vitro mechanistic work behind the assumed BDNF/NGF upregulation claim.
- PubMed. N-Acetyl Semax ↗· Sparse, illustrates how little the specific N-acetyl variant has been independently studied.
- ClinicalTrials.gov. Semax registered trials ↗· Check for any registered/Western trials; relevant to FDA/PCAC compounding-review status.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.